Neuberger Berman Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Neuberger Berman Group’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$82K	Buy	26,694 +2,684	+11%	+$10.4K	﹤0.01%	2092
2025 Q4	$98.2K	Buy	24,010 +6,937	+41%	+$34.4K	﹤0.01%	2018
2025 Q3	$83.3K	Sell	17,073 -80	-0.5%	-$420	﹤0.01%	1981
2025 Q2	$86.8K	Buy	17,153 +6,384	+59%	+$31.4K	﹤0.01%	1970
2025 Q1	$57K	Buy	10,769 +469	+5%	+$3.42K	﹤0.01%	1906
2024 Q4	$69.6K	Sell	10,300 -219,538	-96%	-$1.48M	﹤0.01%	1869
2024 Q3	$1.51M	Sell	229,838 -125,801	-35%	-$902K	﹤0.01%	1190
2024 Q2	$2.67M	Buy	+355,639	New	+$3.1M	﹤0.01%	1046

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Neuberger Berman Group's RXRX Position: Q1 2026 in Review

Neuberger Berman Group increased its Recursion Pharmaceuticals (RXRX) stake by 11% in Q1 2026, buying an estimated $10.4K and bringing the position to 26,694 shares worth $82K. The position accounts for ﹤0.01% of the portfolio, ranked #2092.

Neuberger Berman Group first reported a position in RXRX in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.67M in Q2 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Neuberger Berman Group held 26,694 shares of Recursion Pharmaceuticals worth $82K as of Q1 2026.
Neuberger Berman Group bought 2,684 Recursion Pharmaceuticals shares in Q1 2026, an estimated $10.4K.
Recursion Pharmaceuticals made up ﹤0.01% of Neuberger Berman Group's portfolio in Q1 2026, its #2092 holding.
Neuberger Berman Group first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
Neuberger Berman Group's Recursion Pharmaceuticals position peaked at $2.67M in Q2 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.